Möchten Sie immer auf dem neuesten Stand bleiben?

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – ...

Fort Lauderdale, FL, April 09, 2026 (GLOBE NEWSWIRE) -- The presence of microplastics and nanoplastics (MNPs) in the human heart has been gaining attention in recent years. A study back in 2024...

iHerb today announced an exclusive international partnership with k2o, a new hydration and beauty drink, founded by Kylie Jenner.

Privia Health to Report First Quarter 2026 Results Before Market Open on Thursday, May 7

WEST LAFAYETTE, Ind., April 08, 2026 (GLOBE NEWSWIRE) -- Professionals at federally qualified health centers, mental health centers, social service agencies, hospitals, institutes of higher...

San Antonio, TX, April 07, 2026 (GLOBE NEWSWIRE) -- Methodist Healthcare Ministries of South Texas, Inc. (MHM) is investing $237.5 million in 2026 — an 11 percent increase over its 2025 commitment —...

American Botanical Council presented Natural Remedies with the 2026 ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award.

Former CMMI Chief Informatics Officer and physician Will Gordon brings deep experience at the intersection of clinical care, health policy and enterprise technology BOSTON, April 07, 2026 (GLOBE...

Des études de phase 2 sur le lunsekimig ont atteint les critères d’évaluation principaux et secondaires clés dans deux maladies respiratoires

Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.